Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Invokana, Farxiga New Safety Warning May Give Jardiance Market Edge

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA strengthens warning about risk of acute kidney injury for two SGLT2 inhibitors but not Jardiance, the only diabetes drug with data on cardiovascular benefit.

You may also be interested in...



Invokana Adds Warnings On Amputation Risk, But Will It Give Jardiance An Edge?

New data from J&J's cardiovascular outcomes trials shows leg and foot amputations occurred about twice as often in diabetes patients treated with canagliflozin versus placebo.

Merck/Pfizer's Latest SGLT-2 Data Support Attractive Ertugliflozin/Januvia Combo

Overall, data suggest a profile similar to J&J's market-leading Invokana, but analysts still see room for a new entrant to the anti-SGLT-2 class in type 2 diabetes.

FDA Warning On SGLT-2 Drugs Raises Specter Of Labeling Change

FAERS reports identify cases of diabetic ketoacidosis, ordinarily rare in type 2 diabetes, which were not associated with high blood sugar levels.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel